Other Issues

Browse Other Issues Content

Submission

Supply chain resilience is essential to assure consumer healthcare products Americans depend on remain widely available, including in times of disease outbreaks or global crises.

Dec 23, 2020

Press Releases and Statements

CHPA released the following statement in response to FDA’s warning that consumers avoid certain male enhancement and weight loss products sold by major online retailers due to hidden, potentially dangerous drug ingredients.

Dec 18, 2020

Press Releases and Statements

Expert insights on the importance of proactive health maintenance, including addressing nutrient deficiencies that increase risk of infection and disease.

Dec 15, 2020

Press Releases and Statements

Today’s column in the Los Angeles Times is aligned with calls from responsible manufacturers in the dietary supplement industry who agree that regulations need to be modernized and strengthened.

Dec 15, 2020

Submission

The breadth of the proposed rule would create a heavy workload on agencies within HHS, diverting attention from more pressing work. CHPA requests an extension of the comment period

Dec 4, 2020

Research Reports

This update includes any new statutes or laws passed in states regarding CBD labeling laws, as well as including any regulatory standards regarding CBD labeling laws in those states from spring to fall 2020.

Dec 1, 2020

Research Reports

State by state listing of what entities are permitted to alter controlled substance schedules.

Dec 1, 2020

Research Reports

This report evaluates environmental stressors to coral in the Florida Reef Tract with a focus on the Florida Keys through the lens of accepted global and local factors.

Nov 18, 2020

Press Releases and Statements

When used appropriately, dietary supplements can play an important role in personal healthcare by filling nutritional gaps, supporting certain condition-specific needs, promoting healthy body functions, and contributing to overall wellness.

Nov 18, 2020

Submission

As FDA is recognized as an authoritative body by Proposition 65, we believe that OEHHA should await the outcome of FDA's review rather than bringing BP-3 to the DARTIC for review.

Nov 16, 2020

Filter Results